Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.

IFCC interim guidelines on biochemical/hematological monitoring of COVID-19 patients

Mancini, Nicasio;Clementi, Massimo;
2020-01-01

Abstract

Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.
2020
2020
COVID-19; SARS-CoV-2; biochemistry; hematology
Thompson, Simon; Bohn, Mary Kathryn; Mancini, Nicasio; Loh, Tze Ping; Wang, Cheng-Bin; Grimmler, Matthias; Yuen, Kwok-Yung; Mueller, Robert; Koch, Dav...espandi
File in questo prodotto:
File Dimensione Formato  
96) 2020- IFCC interim guidelines on biochemical-hematological monitoring of COVID-19 patients.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 242.19 kB
Formato Adobe PDF
242.19 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2148965
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 26
social impact